Shares of DXC Technology cratered 18.1% to $8.81 on September 19, extending a brutal week that has erased roughly 27% of the company's value in five trading sessions — a slide that unfolded while broader markets held firm, underscoring that this is a company-specific crisis of confidence, not a macro event. DXC Technology Loses a Quarter of Its Value in a Week — Is This a Shrinking Business or a Turnaround Waiting to Happen?
Shares of DXC Technology plummeted 18.1% to $8.81 on September 19, torching roughly 27% of the stock's value in five sessions after an analyst downgrade to Sell flagged persistent revenue erosion and doubts that artificial intelligence efforts can rescue the company's shrinking core business. The selloff came while broader markets traded higher, signaling this is a DXC-specific reckoning.
• Revenue Is Heading in the Wrong Direction — and Accelerating Downhill. Organic revenue decline accelerated to 6.6% in the fourth quarter of fiscal 2026, up from 4.3% the prior quarter.
Full-year fiscal 2026 revenue landed at $12.64 billion, down 1.8%. Worse, fiscal 2027 guidance projects another 3% to 5% organic revenue decline, with total revenue expected between $12.11 billion and $12.35 billion. For shareholders, this means the top line is still shrinking with no stabilization in sight — and each quarter of decline makes it harder for the company to maintain its cost structure.
• AI Promises Sound Good on Paper, But the Numbers Don't Back Them Up. DXC is seeing ongoing revenue contraction and heightened vulnerability to AI disruption in its core business segments. Despite a 5% year-over-year bookings increase and a new AI orchestration system, DXC has guided for a further 4% overall revenue decline in fiscal 2027.
Management aims for AI-infused solutions to comprise 10% of its business within 36 months , but that target sits against a backdrop of rising selling and R&D costs per dollar of gross profit and declining gross margins. In plain terms: spending on AI is going up, but revenue is still going down.
• Wall Street Has Run Out of Patience. DXC now carries an average analyst rating of "Reduce" across nine covering firms.
The average price target is $11.45, but that figure has been revised downward by 15.8% in the past three months alone. At $8.81, the stock is now trading well below even the lowered consensus — a sign the market is pricing in structural decline, not a temporary stumble.
• The Balance Sheet Offers Some Cushion, But Not a Fix. Free cash flow rose modestly to $713 million in fiscal 2026 , and the company guides to roughly $600 million in fiscal 2027. That cash keeps the lights on, but GAAP net income was a razor-thin $18 million — a 95.2% collapse year-over-year — with diluted earnings per share of just $0.10. Cost-cutting can only carry a company so far when revenue keeps falling. Until DXC shows it can actually grow again, this stock trades as a melting ice cube — and today's downgrade suggests the melt is speeding up.